Carla Boquimpani

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson et al. · Leukemia · 2021 · 332 citations · Full text

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Delphine Réa, Michael J. Mauro, Carla Boquimpani et al. · Blood · 2021 · 319 citations · Full text

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

François-Xavier Mahon, Carla Boquimpani, Dong‐Wook Kim et al. · Annals of Internal Medicine · 2018 · 127 citations · Full text

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Andreas Hochhaus, Delphine Réa, Carla Boquimpani et al. · Leukemia · 2023 · 126 citations · Full text

Mixed-phenotype Acute Leukemia, Asciminib Vs Bosutinib, Pharmacotherapy +17

Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients—An analysis from the Brazilian Hodgkin Lymphoma Registry

Irène Biasoli, Nelson Castro, Márcia Torresan Delamain et al. · International Journal of Cancer · 2017 · 33 citations · Full text